21 completed, 7 terminated, 3 unknown, 1 withdrawn. 20 Phase 1, 12 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 14, Terminated 4, Unknown 1, Withdrawn 1 |
| Phase 2 | 12 | Completed 8, Terminated 3, Unknown 1 |
| Phase 3 | 2 | Unknown 2 |
Follow DAC: new trials by email Literature Review of DAC trials Research Report on DAC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS Decitabine, Arsenic Trioxide - P53 Mutation, Myeloid Malignancy | Phase 1 | Unknown | Ruijin Hospital | 5 | 2018-01-10 | 2022-11-04 |
| Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Pacritinib, Cytarabine, Daunorubicin Hydrochloride - Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 1 | Completed | Bhavana Bhatnagar | 13 | 2016-01-12 | 2019-01-25 |
| Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, natural killer cell therapy, aldesleukin - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Sumithira Vasu | 8 | 2015-04-21 | 2020-03-09 |
| Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation Vaccine - Acute Myelogenous Leukemia | Phase 1 | Withdrawn | University of Louisville | 2015-03-01 | 2017-05-09 | |
| Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations Arm A Mylotarg plus DA Versus CPX-351, Arm B Vosaroxin and Decitabine, Arm D Small molecule or Not - Acute Myeloid Leukaemia, Myelodysplastic Syndrome | Phase 2 / Phase 3 | Unknown | Cardiff University | 1600 | 2014-10-30 | 2020-01-23 |
| Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia cytarabine, omacetaxine mepesuccinate, decitabine - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Terminated | Roswell Park Cancer Institute | 2 | 2014-07-01 | 2016-05-09 |
| Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia decitabine, selinexor, pharmacological study - Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 1 | Completed | Bhavana Bhatnagar | 25 | 2014-03-01 | 2017-12-08 |
| Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia DAC, CLAG, Consolidation, I HAM cycle - Acute Myeloid Leukemia | Phase 3 | Unknown | dr hab. n. med. Agnieszka Wierzbowska | 400 | 2014-02-01 | 2014-02-27 |
| AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia HDAC inhibitor AR-42, decitabine, laboratory biomarker analysis - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Alison Walker | 13 | 2013-09-17 | 2018-03-14 |
| Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Decitabine, Midostaurin - Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults, AML (Adult) With 11q23 (MLL) Abnormalities | Phase 2 | Terminated | David Iberri | 13 | 2013-06-01 | 2018-09-27 |
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk Decitabine, Azacitidine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 113 | 2012-11-06 | 2020-12-24 |
| Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms Induction Chemotherapy, Consolidation Chemotherapy, Autologous Stem Cell Transplantation - Acute Myeloid Leukemia, Myeloproliferative Neoplasms | Phase 2 | Completed | Hospital Israelita Albert Einstein | 455 | 2012-10-01 | 2016-11-08 |
| Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS decitabine, idarubicin, cytarabine - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 7 | 2012-07-01 | 2017-03-31 |
| Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome tosedostat, cytarabine, decitabine - Acute Myeloid Leukemia With Multilineage Dysplasia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | Fred Hutchinson Cancer Center | 34 | 2012-05-01 | 2017-02-15 |
| Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome flow cytometry, DNA methylation analysis, cytogenetic analysis - Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 25 | 2010-07-01 | 2019-03-04 |
| Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride - Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2009-04-01 | 2022-08-01 |
| Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors peginterferon alfa-2b, decitabine, laboratory biomarker analysis - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2009-04-01 | 2014-02-24 |
| Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia bortezomib, decitabine, pharmacological study - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Completed | National Cancer Institute (NCI) | 19 | 2008-06-01 | 2014-11-07 |
| Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia Decitabine (USAN, INN) - Thalassemia | Phase 2 | Completed | Carelon Research | 6 | 2008-01-01 | 2014-04-25 |
| Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia decitabine, laboratory biomarker analysis, pharmacological study - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2007-05-01 | 2016-06-27 |
Showing 20 of 32. Sign in to see all of them.
Leukemia, Myeloid, Acute (17) · Congenital Abnormalities (13) · Myelodysplastic Syndromes (4) · Anemia, Refractory, with Excess of Blasts (3) · Leukemia, Myelomonocytic, Chronic (3) · Myeloproliferative Disorders (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Blast Crisis (2) · Burkitt Lymphoma (2) · Leukemia (2) · Leukemia, Erythroblastic, Acute (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Megakaryoblastic, Acute (2) · Leukemia, Monocytic, Acute (2) · Leukemia, Myelomonocytic, Acute (2)
National Cancer Institute (NCI) (15) · Bhavana Bhatnagar (2) · Fred Hutchinson Cancer Center (2) · Roswell Park Cancer Institute (2) · Alison Walker (1) · Cardiff University (1) · Carelon Research (1) · Case Comprehensive Cancer Center (1) · David Iberri (1) · Hospital Israelita Albert Einstein (1) · M.D. Anderson Cancer Center (1) · Ruijin Hospital (1) · Sumithira Vasu (1) · University of Louisville (1) · dr hab. n. med. Agnieszka Wierzbowska (1)
United States (26) · Canada (3) · Brazil (1) · China (1) · Denmark (1) · Poland (1) · United Kingdom (1)
Bhavana Bhatnagar, DO (2) · Jean-Pierre Issa (2) · Kristie Blum (2) · William Blum (2) · Alison Walker, MD (1) · Brenda Cooper, MD (1) · David J Iberri, MD (1) · David Stewart (1) · Derek Stirewalt (1) · Elias Jabbour, MD (1) · Evelena Ontiveros (1) · Fabio P Santos, MD (1) · Gregory Otterson (1) · Jeffrey Weber (1) · John Pagel (1)
PMID 23660685, PMID 17679729, PMID 20368434, PMID 21700776, PMID 22566605, PMID 25621498, PMID 26943915, PMID 28774880, PMID 31545113, PMID 31661339, PMID 38319837, PMID 41237344
U01CA076576 (4), N01CM62207 (2), P30CA015704 (2), U01CA062461 (2), U01CA097452 (2), N01CM62202 (1), N01CM62203 (1), P30CA016056 (1), P30CA016058 (1), P30CA016672 (1), R21CA110496 (1), R21CA122270 (1), U01CA062505 (1), U01CA132123 (1), U01HL065238 (1)